{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:12:42Z","timestamp":1790482362721,"version":"4.1.0"},"reference-count":141,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012542","name":"Sichuan Province Science and Technology Support Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.ejmech.2022.114176","type":"journal-article","created":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T11:38:11Z","timestamp":1643888291000},"page":"114176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"special_numbering":"C","title":["Recent advances of human dihydroorotate dehydrogenase inhibitors for cancer therapy: Current development and future perspectives"],"prefix":"10.1016","volume":"232","author":[{"given":"Lele","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifa","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyu","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2022.114176_bib1","doi-asserted-by":"crossref","first-page":"688","DOI":"10.3390\/cancers11050688","article-title":"Cancer cells tune the signaling pathways to empower de novo synthesis of nucleotides","volume":"11","author":"Villa","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2022.114176_bib2","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1158\/2159-8290.CD-16-0611","article-title":"Adaptive reprogramming of de novo pyrimidine synthesis is a metabolic vulnerability in triple-negative breast cancer","volume":"7","author":"Brown","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2022.114176_bib3","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.4049\/jimmunol.169.6.3392","article-title":"Restriction of de novo pyrimidine biosynthesis inhibits Th1 cell activation and promotes Th2 cell differentiation","volume":"169","author":"Dimitrova","year":"2002","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ejmech.2022.114176_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.02.005","article-title":"A\u00a0non-proliferative role of pyrimidine metabolism in cancer","volume":"35","author":"Siddiqui","year":"2020","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.ejmech.2022.114176_bib5","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jgg.2015.04.004","article-title":"Pyrimidine metabolism: dynamic and versatile pathways in pathogens and cellular development","volume":"42","author":"Garavito","year":"2015","journal-title":"Journal of Genetics and Genomics"},{"key":"10.1016\/j.ejmech.2022.114176_bib6","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.molmed.2005.07.003","article-title":"Pyrimidine pathways in health and disease","volume":"11","author":"Loffler","year":"2005","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ejmech.2022.114176_bib7","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a040592","article-title":"Nucleotide metabolism","volume":"13","author":"Chandel","year":"2021","journal-title":"Cold Spring Harbor Perspect. Biol."},{"key":"10.1016\/j.ejmech.2022.114176_bib8","doi-asserted-by":"crossref","first-page":"1656S","DOI":"10.1093\/jn\/137.6.1656S","article-title":"Orotic acid excretion and arginine metabolism","volume":"137","author":"Brosnan","year":"2007","journal-title":"J.\u00a0Nutr."},{"key":"10.1016\/j.ejmech.2022.114176_bib9","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature12445","article-title":"Pyrimidine homeostasis is accomplished by directed overflow metabolism","volume":"500","author":"Reaves","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.114176_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2020.165759","article-title":"Dihydroorotate dehydrogenase in oxidative phosphorylation and cancer","volume":"1866","author":"Boukalova","year":"2020","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Basis Dis."},{"key":"10.1016\/j.ejmech.2022.114176_bib11","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2174\/138955711797247707","article-title":"Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors","volume":"11","author":"Vyas","year":"2011","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114176_bib12","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1089\/ars.2012.4845","article-title":"Mitochondrial respiratory supercomplex association limits production of reactive oxygen species from complex I","volume":"19","author":"Maranzana","year":"2013","journal-title":"Antioxidants Redox Signal."},{"key":"10.1016\/j.ejmech.2022.114176_bib13","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41586-020-2475-6","article-title":"Mitochondrial ubiquinol oxidation is necessary for tumour growth","volume":"585","author":"Martinez-Reyes","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.114176_bib14","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.biochi.2017.02.003","article-title":"Dihydroorotate dehydrogenase (DHODH) inhibitors affect ATP depletion, endogenous ROS and mediate S-phase arrest in breast cancer cells","volume":"135","author":"Mohamad Fairus","year":"2017","journal-title":"Biochimie"},{"key":"10.1016\/j.ejmech.2022.114176_bib15","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.cmet.2018.10.014","article-title":"Reactivation of dihydroorotate dehydrogenase-driven pyrimidine biosynthesis restores tumor growth of respiration-deficient cancer cells","volume":"29","author":"Bajzikova","year":"2019","journal-title":"Cell Metabol."},{"key":"10.1016\/j.ejmech.2022.114176_bib16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.pharmthera.2018.10.012","article-title":"Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer","volume":"195","author":"Madak","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2022.114176_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41368-020-00109-x","article-title":"SOX2-dependent expression of dihydroorotate dehydrogenase regulates oral squamous cell carcinoma cell proliferation","volume":"13","author":"Qiu","year":"2021","journal-title":"Int. J. Oral Sci."},{"key":"10.1016\/j.ejmech.2022.114176_bib18","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.7150\/jca.14835","article-title":"Dihydroorotate dehydrogenase inhibitors target c-Myc and arrest melanoma, myeloma and lymphoma cells at S-phase","volume":"8","author":"Dorasamy","year":"2017","journal-title":"J.\u00a0Cancer"},{"key":"10.1016\/j.ejmech.2022.114176_bib19","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cell.2016.08.057","article-title":"Inhibition of dihydroorotate dehydrogenase overcomes differentiation blockade in acute myeloid leukemia","volume":"167","author":"Sykes","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2022.114176_bib20","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw7852","article-title":"Identification of DHODH as a therapeutic target in small cell lung cancer","volume":"11","author":"Li","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2022.114176_bib21","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.chembiol.2018.03.005","article-title":"Dependence on the pyrimidine biosynthetic enzyme DHODH is a synthetic lethal vulnerability in mutant KRAS-driven cancers","volume":"25","author":"Koundinya","year":"2018","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.ejmech.2022.114176_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0002722","article-title":"Global regulation of nucleotide biosynthetic genes by c-Myc","volume":"3","author":"Liu","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2022.114176_bib23","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1080\/14728222.2018.1536748","article-title":"The emergence of dihydroorotate dehydrogenase (DHODH) as a therapeutic target in acute myeloid leukemia","volume":"22","author":"Sykes","year":"2018","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ejmech.2022.114176_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1009117","article-title":"Inhibition of the de novo pyrimidine biosynthesis pathway limits ribosomal RNA transcription causing nucleolar stress in glioblastoma cells","volume":"16","author":"Lafita-Navarro","year":"2020","journal-title":"PLoS Genet."},{"key":"10.1016\/j.ejmech.2022.114176_bib25","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau4972","article-title":"Targeting pyrimidine synthesis accentuates molecular therapy response in glioblastoma stem cells","volume":"11","author":"Wang","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2022.114176_bib26","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/s41467-018-03441-3","article-title":"A\u00a0DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage","volume":"9","author":"Ladds","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2022.114176_bib27","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nature09882","article-title":"DHODH modulates transcriptional elongation in the neural crest and melanoma","volume":"471","author":"White","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.114176_bib28","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/stem.3290","article-title":"Selective eradication of pluripotent stem cells by inhibiting DHODH activity","volume":"39","author":"Kondo","year":"2021","journal-title":"Stem Cell."},{"key":"10.1016\/j.ejmech.2022.114176_bib29","doi-asserted-by":"crossref","first-page":"105096","DOI":"10.1016\/j.tiv.2021.105096","article-title":"Investigating dihydroorotate dehydrogenase inhibitor mediated mitochondrial dysfunction in hepatic in\u00a0vitro models","volume":"72","author":"Jones","year":"2021","journal-title":"Toxicol. Vitro"},{"key":"10.1016\/j.ejmech.2022.114176_bib30","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2174\/13816128113199990584","article-title":"Comparison of two molecular scaffolds, 5-methylisoxazole-3-carboxamide and 5-methylisoxazole-4-carboxamide","volume":"20","author":"Song","year":"2014","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.ejmech.2022.114176_bib31","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.toxlet.2017.10.013","article-title":"Anti-inflammatory drug, Leflunomide and its metabolite Teriflunomide inhibit NSCLC proliferation in\u00a0vivo and in\u00a0vitro","volume":"282","author":"Jiang","year":"2018","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.ejmech.2022.114176_bib32","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/j.ijrobp.2021.07.205","article-title":"Identification of de novo pyrimidine synthesis as a targetable vulnerability in a novel IDH1 mutant engineered astrocytoma model","volume":"111","author":"Shi","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ejmech.2022.114176_bib33","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1021\/jm0506975","article-title":"Dual binding mode of a novel series of DHODH inhibitors","volume":"49","author":"Baumgartner","year":"2006","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114176_bib34","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1080\/15257770.2019.1708100","article-title":"Preparation of human dihydroorotate dehydrogenase for interaction studies with lipid bilayers","volume":"39","author":"Rodriguez","year":"2020","journal-title":"Nucleos Nucleot. Nucleic Acids"},{"key":"10.1016\/j.ejmech.2022.114176_bib35","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0969-2126(00)00077-0","article-title":"Structures of human dihydroorotate dehydrogenase in complex with antiproliferative agents","volume":"8","author":"Liu","year":"2000","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2022.114176_bib36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1535-7163.MCT-18-0863","article-title":"Targeting of hematologic malignancies with PTC299, A novel potent inhibitor of dihydroorotate dehydrogenase with favorable pharmaceutical properties","volume":"18","author":"Cao","year":"2019","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2022.114176_bib37","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1046\/j.1432-1327.2000.01213.x","article-title":"Requirements for the mitochondrial import and localization of dihydroorotate dehydrogenase","volume":"267","author":"Rawls","year":"2000","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.ejmech.2022.114176_bib38","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/2211-5463.12403","article-title":"Crystal structures of FMN-bound and FMN-free forms of dihydroorotate dehydrogenase from Trypanosoma brucei","volume":"8","author":"Kubota","year":"2018","journal-title":"Febs Open Bio"},{"key":"10.1016\/j.ejmech.2022.114176_bib39","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0969-2126(00)00530-X","article-title":"Structure of dihydroorotate dehydrogenase B: electron transfer between two flavin groups bridged by an iron-sulphur cluster","volume":"8","author":"Rowland","year":"2000","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2022.114176_bib40","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0965-1748(02)00052-8","article-title":"Drosophila melanogaster dihydroorotate dehydrogenase: the N-terminus is important for biological function in\u00a0vivo but not for catalytic properties in\u00a0vitro","volume":"32","author":"L\u00f6ffler","year":"2002","journal-title":"Insect Biochem. Mol. Biol."},{"key":"10.1016\/j.ejmech.2022.114176_bib41","doi-asserted-by":"crossref","first-page":"111681","DOI":"10.1016\/j.ejmech.2019.111681","article-title":"Dihydroorotate dehydrogenase inhibitors in anti-infective drug research","volume":"183","author":"Boschi","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114176_bib42","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1021\/bi00429a040","article-title":"Analysis of the kinetic mechanism of the bovine liver mitochondrial dihydroorotate dehydrogenase","volume":"28","author":"Hines","year":"1989","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2022.114176_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/bse0470001","article-title":"The mitochondrial respiratory chain","volume":"47","author":"Rich","year":"2010","journal-title":"Essays Biochem."},{"key":"10.1016\/j.ejmech.2022.114176_bib44","doi-asserted-by":"crossref","DOI":"10.1177\/2040622320944773","article-title":"Teriflunomide preserves peripheral nerve mitochondria from oxidative stress-mediated alterations","volume":"11","author":"Malla","year":"2020","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.ejmech.2022.114176_bib45","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41586-021-03539-7","article-title":"DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer","volume":"593","author":"Mao","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.114176_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-021-00656-7","article-title":"DHODH tangoing with GPX4 on the ferroptotic stage","volume":"6","author":"Wang","year":"2021","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"10.1016\/j.ejmech.2022.114176_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40170-021-00250-z","article-title":"DHODH and cancer: promising prospects to be explored","volume":"9","author":"Zhou","year":"2021","journal-title":"Cancer Metabol."},{"key":"10.1016\/j.ejmech.2022.114176_bib48","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/ng.499","article-title":"Exome sequencing identifies the cause of a mendelian disorder","volume":"42","author":"Ng","year":"2010","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmech.2022.114176_bib49","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.3390\/cancers11121895","article-title":"Identification of circulating genomic and metabolic biomarkers in intrahepatic cholangiocarcinoma","volume":"11","author":"Winter","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2022.114176_bib50","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1038\/s41375-019-0461-5","article-title":"The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies","volume":"33","author":"Christian","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2022.114176_bib51","doi-asserted-by":"crossref","first-page":"13918","DOI":"10.1021\/acs.jmedchem.1c01402","article-title":"Exploring marine-derived ascochlorins as novel human dihydroorotate dehydrogenase inhibitors for treatment of triple-negative breast cancer","volume":"64","author":"Luo","year":"2021","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114176_bib52","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s10495-011-0667-0","article-title":"Evidence supporting a role for dihydroorotate dehydrogenase, bioenergetics, and p53 in selective Teriflunomide-induced apoptosis in transformed versus normal human keratinocytes","volume":"17","author":"Hail","year":"2012","journal-title":"Apoptosis"},{"key":"10.1016\/j.ejmech.2022.114176_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41389-019-0161-z","article-title":"UVB-induced DHODH upregulation, which is driven by STAT3, is a promising target for chemoprevention and combination therapy of photocarcinogenesis","volume":"8","author":"Hosseini","year":"2019","journal-title":"Oncogenesis"},{"key":"10.1016\/j.ejmech.2022.114176_bib54","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.omto.2019.04.006","article-title":"Leflunomide synergizes with gemcitabine in growth inhibition of PC cells and impairs c-Myc signaling through PIM kinase targeting","volume":"14","author":"Buettner","year":"2019","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.ejmech.2022.114176_bib55","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.52135","article-title":"PCK1 and DHODH drive colorectal cancer liver metastatic colonization and hypoxic growth by promoting nucleotide synthesis","volume":"8","author":"Yamaguchi","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.ejmech.2022.114176_bib56","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.cell.2012.01.058","article-title":"Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism","volume":"149","author":"Ying","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2022.114176_bib57","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1158\/2159-8290.CD-16-0612","article-title":"PTEN regulates glutamine flux to pyrimidine synthesis and sensitivity to dihydroorotate dehydrogenase inhibition","volume":"7","author":"Mathur","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2022.114176_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-020-03044-1","article-title":"Elevated DHODH expression promotes cell proliferation via stabilizing \u03b2-catenin in esophageal squamous cell carcinoma","volume":"11","author":"Qian","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2022.114176_bib59","series-title":"FASEB JOURNAL","first-page":"A1018","article-title":"Regulated complex formation between MAP kinase, PKA and their mutual substrate CAD","author":"Di Gregorio","year":"2003"},{"key":"10.1016\/j.ejmech.2022.114176_bib60","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1586\/17512433.2015.1019343","article-title":"Leflunomide and Teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases","volume":"8","author":"Fragoso","year":"2015","journal-title":"Expet Rev. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114176_bib61","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s10067-017-3687-5","article-title":"Clinical effectiveness and safety of Leflunomide in inflammatory arthritis: a report from the RAPPORT database with supporting patient survey","volume":"36","author":"Schultz","year":"2017","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.ejmech.2022.114176_bib62","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s10067-019-04577-3","article-title":"Reversible alopecia areata: a little known side effect of Leflunomide","volume":"38","author":"Koller","year":"2019","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.ejmech.2022.114176_bib63","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/1097-0142(19890115)63:2<243::AID-CNCR2820630207>3.0.CO;2-7","article-title":"Mucocutaneous side effects of Brequinar sodium. A new inhibitor of pyrimidine de novo biosynthesis","volume":"63","author":"Schwartsmann","year":"1989","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2022.114176_bib64","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1080\/15257770.2018.1508692","article-title":"Re-evaluation of Brequinar sodium, a dihydroorotate dehydrogenase inhibitor","volume":"37","author":"Peters","year":"2018","journal-title":"Nucleos Nucleot. Nucleic Acids"},{"key":"10.1016\/j.ejmech.2022.114176_bib65","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1182\/blood-2018-99-110570","article-title":"Preliminary results of a phase 2a dose optimization study of ASLAN003 (DHODH inhibitor) in acute myeloid leukemia (AML) patients who are ineligible for standard therapy; early signs of activity","volume":"132","author":"Ting","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2022.114176_bib66","doi-asserted-by":"crossref","first-page":"5152","DOI":"10.1182\/blood-2019-124569","article-title":"Inhibition of de novo pyrimidine nucleotide synthesis by the novel DHODH inhibitor PTC299 induces differentiation and\/or death of AML cells","volume":"134","author":"Weetall","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2022.114176_bib67","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1158\/1535-7163.MCT-20-0550","article-title":"Selective vulnerability to pyrimidine starvation in hematologic malignancies revealed by AG-636, a novel clinical-stage inhibitor of dihydroorotate dehydrogenase","volume":"19","author":"McDonald","year":"2020","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2022.114176_bib68","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2019-123471","article-title":"Hematologic malignancies exhibit selective vulnerability to inhibition of de novo pyrimidine biosynthesis by AG-636, a novel inhibitor of dihydroorotate dehydrogenase in phase 1 clinical trials","volume":"134","author":"Ulanet","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2022.114176_bib69","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1182\/blood-2019-125469","article-title":"Targeting DHODH with AG-636 induces apoptosis and differentiation and inhibits mitochondrial function in AML, translating into anti-tumor efficacy in\u00a0vitro and in\u00a0vivo","volume":"134","author":"Zeng","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2022.114176_bib70","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1158\/1538-7445.AM2020-234","article-title":"A\u00a0novel, small molecule inhibitor of dihydroorotate dehydrogenase (DHODH), RP7214, potentiates activity of chemotherapeutics in breast and colorectal cancers","volume":"80","author":"Azmi","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114176_bib71","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1158\/1538-7445.AM2021-1256","article-title":"JNJ-74856665, a novel DHODH inhibitor, mediates potent anti-leukemic activity and differentiation in\u00a0vitro and in\u00a0vivo","volume":"81","author":"Pietsch","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114176_bib72","doi-asserted-by":"crossref","first-page":"11417","DOI":"10.1038\/s41598-021-91069-7","article-title":"Combination of consensus and ensemble docking strategies for the discovery of human dihydroorotate dehydrogenase inhibitors","volume":"11","author":"Chilingaryan","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2022.114176_bib73","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1021\/bi952168g","article-title":"The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase","volume":"35","author":"Davis","year":"1996","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2022.114176_bib74","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013128","article-title":"The anti-inflammatory drug leflunomide is an agonist of the aryl hydrocarbon receptor","volume":"5","author":"O'Donnell","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2022.114176_bib75","doi-asserted-by":"crossref","first-page":"9125","DOI":"10.3892\/mmr.2017.7755","article-title":"Leflunomide inhibits proliferation and tumorigenesis of oral squamous cell carcinoma","volume":"16","author":"Ren","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.ejmech.2022.114176_bib76","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.bbrc.2018.01.107","article-title":"Leflunomide: a promising drug with good antitumor potential","volume":"496","author":"Zhang","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2022.114176_bib77","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1093\/ndt\/gfr416","article-title":"Leflunomide with low-dose everolimus for treatment of Kaposi's sarcoma in a renal allograft recipient","volume":"26","author":"Basu","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"issue":"Suppl 129","key":"10.1016\/j.ejmech.2022.114176_bib78","doi-asserted-by":"crossref","first-page":"114","DOI":"10.55563\/clinexprheumatol\/ve38dj","article-title":"Efficacy of leflunomide in the treatment of vasculitis","volume":"39","author":"Mustapha","year":"2021","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.ejmech.2022.114176_bib79","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/s41391-020-0251-1","article-title":"Leflunomide triggers synthetic lethality in PTEN-deficient prostate cancer","volume":"23","author":"Ozturk","year":"2020","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.ejmech.2022.114176_bib80","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1158\/1535-7163.MCT-20-0567","article-title":"Leflunomide suppresses the growth of LKB1-inactivated tumors in the immune-competent host and attenuates distant cancer metastasis","volume":"20","author":"Jin","year":"2021","journal-title":"Mol. Cancer Therapeut."},{"issue":"Pt 2","key":"10.1016\/j.ejmech.2022.114176_bib81","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1042\/bj3360299","article-title":"Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of Leflunomide","volume":"336","author":"Bruneau","year":"1998","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2022.114176_bib82","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/2040622313492810","article-title":"Teriflunomide in relapsing multiple sclerosis: therapeutic utility","volume":"4","author":"Freedman","year":"2013","journal-title":"Therapeutic Advances in Chronic Disease"},{"key":"10.1016\/j.ejmech.2022.114176_bib83","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jneuroim.2013.10.003","article-title":"The effects of Teriflunomide on lymphocyte subpopulations in human peripheral blood mononuclear cells in\u00a0vitro","volume":"265","author":"Li","year":"2013","journal-title":"J.\u00a0Neuroimmunol."},{"key":"10.1016\/j.ejmech.2022.114176_bib84","first-page":"15","article-title":"Emerging oral immunomodulating agents - focus on Teriflunomide for the treatment of multiple sclerosis","volume":"2","author":"Nwankwo","year":"2012","journal-title":"Degener. Neurol. Neuromuscul. Dis."},{"key":"10.1016\/j.ejmech.2022.114176_bib85","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/j.1476-5381.2012.01836.x","article-title":"Profiling of dihydroorotate dehydrogenase, p38 and JAK inhibitors in the rat adjuvant-induced arthritis model: a translational study","volume":"166","author":"Balague","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114176_bib86","first-page":"5563","article-title":"Activity of a novel 4-quinolinecarboxylic acid, NSC 368390 [6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarb oxylic acid sodium salt], against experimental tumors","volume":"45","author":"Dexter","year":"1985","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114176_bib87","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.biopha.2018.11.010","article-title":"Synergistic inhibition of melanoma xenografts by Brequinar sodium and Doxorubicin","volume":"110","author":"Dorasamy","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2022.114176_bib88","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.2353\/ajpath.2010.091227","article-title":"4SC-101, a novel small molecule dihydroorotate dehydrogenase inhibitor, suppresses systemic lupus erythematosus in MRL-(Fas)lpr mice","volume":"176","author":"Kulkarni","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ejmech.2022.114176_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102129","article-title":"Vidofludimus calcium, a next generation DHODH inhibitor for the Treatment of relapsing-remitting multiple sclerosis","volume":"43","author":"Muehler","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.ejmech.2022.114176_bib90","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1124\/jpet.112.192203","article-title":"Vidofludimus inhibits colonic interleukin-17 and improves hapten-induced colitis in rats by a unique dual mode of action","volume":"342","author":"Fitzpatrick","year":"2012","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2022.114176_bib91","doi-asserted-by":"crossref","first-page":"590","DOI":"10.3389\/fphar.2020.00590","article-title":"Repositioning an immunomodulatory drug Vidofludimus as a farnesoid X receptor modulator with therapeutic effects on NAFLD","volume":"11","author":"Zhu","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114176_bib92","series-title":"BAY 2402234: Preclinical Evaluation of a Novel, Selective Dihydroorotate Dehydrogenase (DHODH) Inhibitor for the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL)","first-page":"3597","author":"Eheim","year":"2019"},{"key":"10.1016\/j.ejmech.2022.114176_bib93","series-title":"BAY 2402234: Preclinical Evaluation of a Novel, Selective Dihydroorotate Dehydrogenase (DHODH) Inhibitor for the Treatment of Colorectal Carcinomas","first-page":"3599","author":"Merz","year":"2019"},{"key":"10.1016\/j.ejmech.2022.114176_bib94","series-title":"Discovery of BAY 2402234 by Phenotypic Screening: A Human Dihydroorotate Dehydrogenase (DHODH) Inhibitor in Clinical Trials for the Treatment of Myeloid Malignancies","first-page":"2","author":"Gradl","year":"2019"},{"key":"10.1016\/j.ejmech.2022.114176_bib95","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1182\/bloodadvances.2020001461","article-title":"DHODH inhibition synergizes with DNA-demethylating agents in the treatment of myelodysplastic syndromes","volume":"5","author":"Kayamori","year":"2021","journal-title":"Blood Advances"},{"key":"10.1016\/j.ejmech.2022.114176_bib96","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.3324\/haematol.2019.230482","article-title":"ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia","volume":"105","author":"Zhou","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmech.2022.114176_bib97","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1021\/jm301848w","article-title":"On dihydroorotate dehydrogenases and their inhibitors and uses","volume":"56","author":"Munier-Lehmann","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114176_bib98","first-page":"3521","article-title":"Inhibition of dihydroorotate dehydrogenase activity by Brequinar sodium","volume":"52","author":"Chen","year":"1992","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114176_bib99","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00894-012-1643-5","article-title":"The role of fluorine in stabilizing the bioactive conformation of dihydroorotate dehydrogenase inhibitors","volume":"19","author":"Bonomo","year":"2013","journal-title":"J.\u00a0Mol. Model."},{"key":"10.1016\/j.ejmech.2022.114176_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104373","article-title":"Potent human dihydroorotate dehydrogenase inhibitory activity of new quinoline-4-carboxylic acids derived from phenolic aldehydes: synthesis, cytotoxicity, lipophilicity and molecular docking studies","volume":"105","author":"Petrovic","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2022.114176_bib101","doi-asserted-by":"crossref","first-page":"5162","DOI":"10.1021\/acs.jmedchem.7b01862","article-title":"Design, synthesis, and biological evaluation of 4-quinoline carboxylic acids as inhibitors of dihydroorotate dehydrogenase","volume":"61","author":"Madak","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114176_bib102","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ejmech.2014.05.064","article-title":"Design, synthesis and pharmacological evaluation of novel substituted quinoline-2-carboxamide derivatives as human dihydroorotate dehydrogenase (hDHODH) inhibitors and anticancer agents","volume":"82","author":"Vyas","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114176_bib103","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.bmcl.2019.01.038","article-title":"Synthesis of 2-,4,-6-, and\/or 7-substituted quinoline derivatives as human dihydroorotate dehydrogenase (hDHODH) inhibitors and anticancer agents: 3D QSAR-assisted design","volume":"29","author":"Vyas","year":"2019","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2022.114176_bib104","doi-asserted-by":"crossref","first-page":"8341","DOI":"10.1021\/jm300630p","article-title":"Discovery of diverse human dihydroorotate dehydrogenase inhibitors as immunosuppressive agents by structure-based virtual screening","volume":"55","author":"Diao","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114176_bib105","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1021\/jm501127s","article-title":"Design, synthesis, X-ray crystallographic analysis, and biological evaluation of thiazole derivatives as potent and selective inhibitors of human dihydroorotate dehydrogenase","volume":"58","author":"Zhu","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114176_bib106","first-page":"1","article-title":"Rational design of benzylidenehydrazinyl-substituted thiazole derivatives as potent inhibitors of human dihydroorotate dehydrogenase with in\u00a0vivo anti-arthritic activity","volume":"5","author":"Li","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2022.114176_bib107","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1039\/C7MD00081B","article-title":"Synthesis, structure-activity relationship and binding mode analysis of 4-thiazolidinone derivatives as novel inhibitors of human dihydroorotate dehydrogenase","volume":"8","author":"Zeng","year":"2017","journal-title":"Medchemcomm"},{"key":"10.1016\/j.ejmech.2022.114176_bib108","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.3390\/molecules24152780","article-title":"Structural optimization and structure-activity relationship of 4-thiazolidinone derivatives as novel inhibitors of human dihydroorotate dehydrogenase","volume":"24","author":"Zeng","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2022.114176_bib109","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1021\/acs.jmedchem.9b01658","article-title":"Optimization of tetrahydroindazoles as inhibitors of human dihydroorotate dehydrogenase and evaluation of their activity and in\u00a0vitro metabolic stability","volume":"63","author":"Popova","year":"2020","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114176_bib110","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ejmech.2017.02.017","article-title":"Design, synthesis, biological evaluation and X-ray structural studies of potent human dihydroorotate dehydrogenase inhibitors based on hydroxylated azole scaffolds","volume":"129","author":"Sainas","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114176_bib111","doi-asserted-by":"crossref","first-page":"6034","DOI":"10.1021\/acs.jmedchem.8b00373","article-title":"Targeting myeloid differentiation using potent 2-hydroxypyrazolo[1,5- a]pyridine scaffold-based human dihydroorotate dehydrogenase inhibitors","volume":"61","author":"Sainas","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114176_bib112","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.3390\/cancers13051003","article-title":"The synergism between DHODH inhibitors and dipyridamole leads to metabolic lethality in acute myeloid leukemia","volume":"13","author":"Gaidano","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2022.114176_bib113","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1021\/acs.jmedchem.0c01549","article-title":"Targeting acute myelogenous leukemia using potent human dihydroorotate dehydrogenase inhibitors based on the 2-hydroxypyrazolo[1,5-a]pyridine scaffold: SAR of the biphenyl moiety","volume":"64","author":"Sainas","year":"2021","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114176_bib114","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1021\/acsmedchemlett.6b00316","article-title":"Development of ML390: a human DHODH inhibitor that induces differentiation in acute myeloid leukemia","volume":"7","author":"Lewis","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114176_bib115","first-page":"795","article-title":"Design, synthesis, molecular modeling, and biological evaluation of acrylamide derivatives as potent inhibitors of human dihydroorotate dehydrogenase for the treatment of rheumatoid arthritis","author":"Zeng","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2022.114176_bib116","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.bmcl.2005.09.045","article-title":"The first de novo designed inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase","volume":"16","author":"Heikkil\u00e4","year":"2006","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2022.114176_bib117","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.chembiol.2019.10.012","article-title":"Metabolic modifier screen reveals secondary targets of protein kinase inhibitors within nucleotide metabolism","volume":"27","author":"Abt","year":"2020","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.ejmech.2022.114176_bib118","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/j.celrep.2018.01.051","article-title":"Differential effector engagement by oncogenic KRAS","volume":"22","author":"Yuan","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2022.114176_bib119","first-page":"7","article-title":"A\u00a0combined chemical, computational and invitro approach identifies SBL 105 as novel DHODH inhibitor in acute myeloid leukemia cells","author":"Kamli","year":"2021","journal-title":"Oncol. Res."},{"key":"10.1016\/j.ejmech.2022.114176_bib120","first-page":"229","article-title":"Discovery of a new pyrimidine synthesis inhibitor eradicating glioblastoma-initiating cells","volume":"22","author":"Echizenya","year":"2020","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ejmech.2022.114176_bib121","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1107\/S2053229617009044","article-title":"Design, synthesis, crystal structure and in\u00a0vitro cytotoxic properties of a novel Schiff base derived from indole and biphenyl","volume":"73","author":"Bu","year":"2017","journal-title":"Acta Crystallogr C Struct Chem"},{"key":"10.1016\/j.ejmech.2022.114176_bib122","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1021\/acschembio.1c00625","article-title":"Identification of dihydroorotate dehydrogenase inhibitors\u2500indoluidins\u2500that inhibit cancer cell growth","volume":"16","author":"Kawatani","year":"2021","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114176_bib123","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1016\/j.bmc.2015.05.051","article-title":"Benzimidazole derivatives as potential dual inhibitors for PARP-1 and DHODH","volume":"23","author":"Abdullah","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114176_bib124","doi-asserted-by":"crossref","first-page":"13875","DOI":"10.1002\/chem.201702999","article-title":"Design, synthesis, and characterization of Brequinar conjugates as probes to study DHODH inhibition","volume":"23","author":"Madak","year":"2017","journal-title":"Chemistry"},{"key":"10.1016\/j.ejmech.2022.114176_bib125","series-title":"Lapachol: an Overview","first-page":"145","author":"Hussain","year":"2007"},{"key":"10.1016\/j.ejmech.2022.114176_bib126","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11101-013-9289-1","article-title":"Lapachol and its congeners as anticancer agents: a review","volume":"13","author":"Epifano","year":"2014","journal-title":"Phytochemistry Rev."},{"key":"10.1016\/j.ejmech.2022.114176_bib127","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-017-1236-x","article-title":"Lapachol, a compound targeting pyrimidine metabolism, ameliorates experimental autoimmune arthritis","volume":"19","author":"Peres","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.ejmech.2022.114176_bib128","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1038\/s41467-019-12607-6","article-title":"The chromosome-scale reference genome of black pepper provides insight into piperine biosynthesis","volume":"10","author":"Hu","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2022.114176_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114000","article-title":"Natural product piperine alleviates experimental allergic encephalomyelitis in mice by targeting dihydroorotate dehydrogenase","volume":"177","author":"Liu","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114176_bib130","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/10408347.2019.1573656","article-title":"Characteristics, biological properties and analytical methods of piperine: a review","volume":"50","author":"Quijia","year":"2020","journal-title":"Crit. Rev. Anal. Chem."},{"key":"10.1016\/j.ejmech.2022.114176_bib131","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104334","article-title":"Mechanisms explaining the efficacy of psoralidin in cancer and osteoporosis, a review","volume":"147","author":"Xin","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2022.114176_bib132","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.3389\/fphar.2019.01589","article-title":"Five constituents in Psoralea corylifolia L. attenuate palmitic acid-induced hepatocyte injury via inhibiting the protein kinase C-\u03b1\/nicotinamide-adenine dinucleotide phosphate oxidase pathway","volume":"10","author":"Zhou","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114176_bib133","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2147\/DDDT.S192681","article-title":"Isobavachalcone isolated from Psoralea corylifolia inhibits cell proliferation and induces apoptosis via inhibiting the AKT\/GSK-3 \u03b2\/\u03b2-catenin pathway in colorectal cancer cells","volume":"13","author":"Li","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejmech.2022.114176_bib134","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.3892\/ol.2017.6517","article-title":"Isobavachalcone inhibits the proliferation and invasion of tongue squamous cell carcinoma cells","volume":"14","author":"Shi","year":"2017","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ejmech.2022.114176_bib135","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3892\/etm.2015.2904","article-title":"Isobavachalcone induces the apoptosis of gastric cancer cells via inhibition of the Akt and Erk pathways","volume":"11","author":"Jin","year":"2016","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.ejmech.2022.114176_bib136","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105483","article-title":"Pharmacological review of isobavachalcone, a naturally occurring chalcone","volume":"165","author":"Wang","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2022.114176_bib137","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.canlet.2010.01.035","article-title":"Abrogation of Akt signaling by Isobavachalcone contributes to its anti-proliferative effects towards human cancer cells","volume":"294","author":"Jing","year":"2010","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2022.114176_bib138","article-title":"Targeting pyrimidine metabolism in the era of precision cancer medicine","volume":"11","author":"Wang","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2022.114176_bib139","article-title":"DHODH inhibition modulates glucose metabolism and circulating GDF15, and improves metabolic balance","volume":"24","author":"Zhang","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.ejmech.2022.114176_bib140","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1093\/bib\/bbaa379","article-title":"A\u00a0comprehensive drug repurposing study for COVID19 treatment: novel putative dihydroorotate dehydrogenase inhibitors show association to serotonin-dopamine receptors","volume":"22","author":"Berber","year":"2021","journal-title":"Briefings Bioinf."},{"key":"10.1016\/j.ejmech.2022.114176_bib141","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.csbj.2019.01.006","article-title":"Bivalent ligands for protein degradation in drug discovery","volume":"17","author":"Scheepstra","year":"2019","journal-title":"Comput. Struct. Biotechnol. J."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422000782?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422000782?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:37:30Z","timestamp":1759329450000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523422000782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":141,"alternative-id":["S0223523422000782"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114176","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances of human dihydroorotate dehydrogenase inhibitors for cancer therapy: Current development and future perspectives","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114176","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114176"}}